- Home
- XFOR vs FNLC Comparison
XFOR vs FNLC Comparison
Compare XFOR & FNLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- FNLC
- Stock Information
- Founded
- XFOR 2014
- FNLC 1864
- Country
- XFOR United States
- FNLC United States
- Employees
- XFOR N/A
- FNLC N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- FNLC Major Banks
- Sector
- XFOR Health Care
- FNLC Finance
- Exchange
- XFOR Nasdaq
- FNLC Nasdaq
- Market Cap
- XFOR 320.0M
- FNLC 303.4M
- IPO Year
- XFOR N/A
- FNLC 1999
- Fundamental
- Price
- XFOR $3.52
- FNLC $25.25
- Analyst Decision
- XFOR Strong Buy
- FNLC
- Analyst Count
- XFOR 3
- FNLC 0
- Target Price
- XFOR $34.67
- FNLC N/A
- AVG Volume (30 Days)
- XFOR 1.7M
- FNLC 20.4K
- Earning Date
- XFOR 11-05-2025
- FNLC 10-22-2025
- Dividend Yield
- XFOR N/A
- FNLC 5.87%
- EPS Growth
- XFOR N/A
- FNLC 18.07
- EPS
- XFOR N/A
- FNLC 2.81
- Revenue
- XFOR $33,979,000.00
- FNLC $88,119,000.00
- Revenue This Year
- XFOR $1,307.51
- FNLC N/A
- Revenue Next Year
- XFOR N/A
- FNLC N/A
- P/E Ratio
- XFOR N/A
- FNLC $8.99
- Revenue Growth
- XFOR 2925.74
- FNLC 12.70
- 52 Week Low
- XFOR $1.35
- FNLC $22.11
- 52 Week High
- XFOR $26.83
- FNLC $30.15
- Technical
- Relative Strength Index (RSI)
- XFOR 49.67
- FNLC 52.81
- Support Level
- XFOR $3.26
- FNLC $24.81
- Resistance Level
- XFOR $3.86
- FNLC $25.50
- Average True Range (ATR)
- XFOR 0.32
- FNLC 0.51
- MACD
- XFOR -0.02
- FNLC 0.10
- Stochastic Oscillator
- XFOR 31.21
- FNLC 74.32
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.